Literature DB >> 28487370

Transactive response DNA-binding protein 43 (TDP-43) regulates alternative splicing of tau exon 10: Implications for the pathogenesis of tauopathies.

Jianlan Gu1,2,3, Feng Chen1,2, Khalid Iqbal2, Cheng-Xin Gong1,2, Xinglong Wang4, Fei Liu5,2.   

Abstract

Hyperphosphorylation and aggregation of the neuronal protein tau are responsible for neurodegenerative diseases called tauopathies. Dysregulation of the alternative splicing of tau exon 10 results in alterations of the ratio of two tau isoforms, 3R-tau and 4R-tau, which have been seen in several tauopathies. Transactive response DNA-binding protein of 43 kDa (TDP-43) is involved in the regulation of RNA processing, including splicing. Cytoplasmic aggregation of TDP-43 has been observed in the brains of individuals with chronic traumatic encephalopathy or Alzheimer's disease, diseases in which neurofibrillary tangles of hyperphosphorylated tau are hallmarks. Here, we investigated the role of TDP-43 in tau exon 10 splicing. We found that TDP-43 promoted tau exon 10 inclusion, which increased production of the 4R-tau isoform. Moreover, TDP-43 could bind to intron 9 of tau pre-mRNA. Deletion of the TDP-43 N or C terminus promoted its cytoplasmic aggregation and abolished or diminished TDP-43-promoted tau exon 10 inclusion. Several TDP-43 mutations associated with amyotrophic lateral sclerosis or frontotemporal lobar degeneration with ubiquitin inclusions promoted tau exon 10 inclusion more effectively than wild-type TDP-43 but did not affect TDP-43 cytoplasmic aggregation in cultured cells. The ratio of 3R-tau/4R-tau was decreased in transgenic mouse brains expressing human TDP-43 and increased in the brains expressing the disease-causing mutation TDP-43M337V, in which cytoplasmic TDP-43 was increased. These findings suggest that TDP-43 promotes tau exon 10 inclusion and 4R-tau expression and that disease-related changes of TDP-43, truncations and mutations, affect its function in tau exon 10 splicing, possibly because of TDP-43 mislocalization to the cytoplasm.
© 2017 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  Alzheimer disease; TAR DNA-binding protein 43 (TDP-43) (TARDBP); alternative splicing; tau protein (tau); tauopathy

Mesh:

Substances:

Year:  2017        PMID: 28487370      PMCID: PMC5481566          DOI: 10.1074/jbc.M117.783498

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  58 in total

1.  Pick's disease associated with the novel Tau gene mutation K369I.

Authors:  M Neumann; W Schulz-Schaeffer; R A Crowther; M J Smith; M G Spillantini; M Goedert; H A Kretzschmar
Journal:  Ann Neurol       Date:  2001-10       Impact factor: 10.422

2.  Structure and novel exons of the human tau gene.

Authors:  A Andreadis; W M Brown; K S Kosik
Journal:  Biochemistry       Date:  1992-11-03       Impact factor: 3.162

3.  Regulation of alternative splicing of human tau exon 10 by phosphorylation of splicing factors.

Authors:  A M Hartmann; D Rujescu; T Giannakouros; E Nikolakaki; M Goedert; E M Mandelkow; Q S Gao; A Andreadis; S Stamm
Journal:  Mol Cell Neurosci       Date:  2001-07       Impact factor: 4.314

4.  Redox signalling directly regulates TDP-43 via cysteine oxidation and disulphide cross-linking.

Authors:  Todd J Cohen; Andrew W Hwang; Travis Unger; John Q Trojanowski; Virginia M Y Lee
Journal:  EMBO J       Date:  2011-12-23       Impact factor: 11.598

Review 5.  TDP-43 and FUS/TLS: emerging roles in RNA processing and neurodegeneration.

Authors:  Clotilde Lagier-Tourenne; Magdalini Polymenidou; Don W Cleveland
Journal:  Hum Mol Genet       Date:  2010-04-15       Impact factor: 6.150

6.  Tau exons 2 and 10, which are misregulated in neurodegenerative diseases, are partly regulated by silencers which bind a SRp30c.SRp55 complex that either recruits or antagonizes htra2beta1.

Authors:  Yingzi Wang; Junning Wang; Lei Gao; Robert Lafyatis; Stefan Stamm; Athena Andreadis
Journal:  J Biol Chem       Date:  2005-02-03       Impact factor: 5.157

7.  Identification of casein kinase-1 phosphorylation sites on TDP-43.

Authors:  Fuyuki Kametani; Takashi Nonaka; Takehiro Suzuki; Tetsuaki Arai; Naoshi Dohmae; Haruhiko Akiyama; Masato Hasegawa
Journal:  Biochem Biophys Res Commun       Date:  2009-03-13       Impact factor: 3.575

8.  Broad clinical phenotypes associated with TAR-DNA binding protein (TARDBP) mutations in amyotrophic lateral sclerosis.

Authors:  Janine Kirby; Emily F Goodall; William Smith; J Robin Highley; Rudo Masanzu; Judith A Hartley; Rachel Hibberd; Hannah C Hollinger; Stephen B Wharton; Karen E Morrison; Paul G Ince; Christopher J McDermott; Pamela J Shaw
Journal:  Neurogenetics       Date:  2009-09-17       Impact factor: 2.660

9.  Phosphorylated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis.

Authors:  Masato Hasegawa; Tetsuaki Arai; Takashi Nonaka; Fuyuki Kametani; Mari Yoshida; Yoshio Hashizume; Thomas G Beach; Emanuele Buratti; Francisco Baralle; Mitsuya Morita; Imaharu Nakano; Tatsuro Oda; Kuniaki Tsuchiya; Haruhiko Akiyama
Journal:  Ann Neurol       Date:  2008-07       Impact factor: 10.422

10.  Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease.

Authors:  M Goedert; M G Spillantini; R Jakes; D Rutherford; R A Crowther
Journal:  Neuron       Date:  1989-10       Impact factor: 17.173

View more
  23 in total

Review 1.  TDP-43 proteinopathy and mitochondrial abnormalities in neurodegeneration.

Authors:  Ju Gao; Luwen Wang; Tingxiang Yan; George Perry; Xinglong Wang
Journal:  Mol Cell Neurosci       Date:  2019-08-21       Impact factor: 4.314

2.  TDP-43 and Tau Oligomers in Alzheimer's Disease, Amyotrophic Lateral Sclerosis, and Frontotemporal Dementia.

Authors:  Mauro Montalbano; Salome McAllen; Filippa Lo Cascio; Urmi Sengupta; Stephanie Garcia; Nemil Bhatt; Anna Ellsworth; Eric A Heidelman; Omar D Johnson; Samantha Doskocil; Rakez Kayed
Journal:  Neurobiol Dis       Date:  2020-10-14       Impact factor: 5.996

3.  Novel monoclonal antibodies targeting the RRM2 domain of human TDP-43 protein.

Authors:  Jorge A Trejo-Lopez; Zachary A Sorrentino; Cara J Riffe; Grace M Lloyd; Sydney A Labuzan; Dennis W Dickson; Anthony T Yachnis; Stefan Prokop; Benoit I Giasson
Journal:  Neurosci Lett       Date:  2020-09-06       Impact factor: 3.046

Review 4.  Triad of TDP43 control in neurodegeneration: autoregulation, localization and aggregation.

Authors:  Paraskevi Tziortzouda; Ludo Van Den Bosch; Frank Hirth
Journal:  Nat Rev Neurosci       Date:  2021-03-02       Impact factor: 34.870

Review 5.  Glial TDP-43 and TDP-43 induced glial pathology, focus on neurodegenerative proteinopathy syndromes.

Authors:  Katherine E Prater; Caitlin S Latimer; Suman Jayadev
Journal:  Glia       Date:  2021-09-24       Impact factor: 7.452

Review 6.  Pathomechanisms of TDP-43 in neurodegeneration.

Authors:  Ju Gao; Luwen Wang; Mikayla L Huntley; George Perry; Xinglong Wang
Journal:  J Neurochem       Date:  2018-02-27       Impact factor: 5.372

Review 7.  Splicing factor SRSF2-centric gene regulation.

Authors:  Kun Li; Ziqiang Wang
Journal:  Int J Biol Sci       Date:  2021-04-16       Impact factor: 6.580

8.  What triggers tauopathy in chronic traumatic encephalopathy?

Authors:  Liam Chen
Journal:  Neural Regen Res       Date:  2018-06       Impact factor: 5.135

9.  Expression of Tau Pathology-Related Proteins in Different Brain Regions: A Molecular Basis of Tau Pathogenesis.

Authors:  Wen Hu; Feng Wu; Yanchong Zhang; Cheng-Xin Gong; Khalid Iqbal; Fei Liu
Journal:  Front Aging Neurosci       Date:  2017-09-27       Impact factor: 5.750

10.  hnRNP A1 Regulates Alternative Splicing of Tau Exon 10 by Targeting 3' Splice Sites.

Authors:  Yongchao Liu; Donggun Kim; Namjeong Choi; Jagyeong Oh; Jiyeon Ha; Jianhua Zhou; Xuexiu Zheng; Haihong Shen
Journal:  Cells       Date:  2020-04-10       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.